The role of the National Institute for Health and Care Excellence (NICE) is to improve outcomes for people using the NHS and other public health and social care services. One of the ways they do this is by developing quality standards and performance metrics for those providing and commissioning health, public health and social care services.
Today marks the deadline for stakeholders to input into NICE quality standards on brain tumours (primary) and brain metastases. The quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It describes high-quality care in priority areas for improvement. These areas include imaging, late effects of treatment and access to rehabilitation.
Hugh Adams, our Head of Stakeholder Relations, said: “As a stakeholder, Brain Tumour Research is happy to act as a critical friend for NICE and believes that the areas as selected by the quality standard represent important areas that relate to the delivery of care to brain tumour patients and their families and carers. However, we are also clear on the need to set standards that are possible to deliver whilst at the same time providing a useful quality index of service delivery for those involved in delivering the service. It is that clarity that has formed both the basis and the content of our submission.
“We welcome the standards and today, we input our concerns about how the quality standards will be implemented and assessed in a collaborative spirit. We hope that those tasked with delivering them will find our focus on these key areas helpful.”
The expected date for publication is 7th December 2021.
You can read more at https://www.nice.org.uk/guidance/indevelopment/gid-qs10092/documents
Related reading:
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.